Zukunftsfonds Heilbronn has increased its stake in Eleva, a manufacturer of superior biologics, by EUR 60 million.

2021-01-14T16:42:43+01:00January 14th, 2021|

The funds will help advance one of its drug candidates, CPV-101,
to stages that will facilitate further investment from venture capitalists and/or pharmaceutical
companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive Board. Read the full article here.